Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock

Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14,285,715 shares of its common stock at a price to the public of $17.50 per share. Gross proceeds to Arcus Biosciences from the offering are expected to be $250.0 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Arcus Biosciences. In addition, Arcus Biosciences has granted the underwriters a 30-day option to purchase up to 2,142,857 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on October 23, 2026, subject to customary closing conditions.